You are here

  • Home
  • Archive
  • Volume 168, Issue 5
  • 5 Rifaximin prophylaxis against travellers’ diarrhoea does nor increase acquisition of extended-spectrum ß – lactamase producing enterobacteriaceae (ESBL-E) in a UK military population travelling to Kenya

Article Text

Article menu
Download PDFPDF
Royal Society of Medicine, Colt Foundation Research Prize Finalists
5 Rifaximin prophylaxis against travellers’ diarrhoea does nor increase acquisition of extended-spectrum ß – lactamase producing enterobacteriaceae (ESBL-E) in a UK military population travelling to Kenya
  1. Tom Troth1,2,
  2. Daniel Burns1,
  3. Chad Porter3,
  4. Joanna Rimmer1,
  5. Jamie Fraser4,5,
  6. Tahaniyat Lalani4,5,6,7,
  7. David Tribble4,6,
  8. Willem Van Schaik2 and
  9. Ramiro Gutierrez3,6
  1. 1Academic Department of Military Medicine, Royal Centre for Defence Medicine, Birmingham, UK
  2. 2Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK
  3. 3Naval Medical Research Center, Silver Springs, MD, USA
  4. 4Infectious Disease Clinical Research Program, Department of Preventative Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
  5. 5Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
  6. 6Department of Preventative Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
  7. 7Naval Medical Center, Portsmoth, VA, USA

Abstract

Background Travellers’ Diarrhoea (TD) is a significant issue for deployed troops. Antibiotic prophylaxis can be effective but raises antimicrobial resistance (AMR) concerns. PREVENT TD study, was a double-blind, randomised, placebo-controlled trial comparing once- and twice-daily rifaximin 550mg against placebo (ClinicalTrials.gov: NCT02498301). Rifaximin showed a protective effect (0.05 vs 0.36/100 person days, p= 0.025 vs placebo) against incident TD. Here we present our results on the acquisition of ESBL-E in PREVENT TD participants.

Methods Enrolled UK subjects deployed to Kenya for 6-week periods. 121 participants provided stool samples upon arrival and prior to departure.

Approximately 100mg of stool was incubated in Luria Broth with cefotaxime (10 μg/ml) at 37°C overnight. Cultures were then spread onto ESBL Chromoselect agar and incubated again overnight. Growth was taken as positive for ESBL-E bacteria. The two rifaximin intervention arms were compared to placebo using Fisher’s exact test.

Bioinformatic analysis has been performed using Parsnp, MLST and Abricate programs.

Results 84/121 (69.4%) subjects had no ESBL-E present on arrival in Kenya. The highest incidence of ESBL acquisition was observed in subjects randomised to the placebo arm; however, the differences were not statistically significant (table in presentation).

In the cohorts colonised with ESBL-E at the start of the study, there was a non-statistically significant reduction in the ESBL-E rates with those taking rifaximin prophylaxis.

Genome sequencing showed a number of ESBL-E E. coli are genetically very similar suggesting a source in Kenya.

Conclusions While ESBL acquisition rate was relatively high (26.5%), rifaximin was not associated with an increase in ESBL acquisition. Further work will be performed to investigate acquisition of rifaximin resistance among commensal Enterobacteriaceae during the trial.

Further Bioinformatic work is ongoing looking at acquisition of resistance genes.

https://doi.org/10.1136/bmjmilitary-2022-RSMabstracts.5

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.